BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement


Subject: BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement
Solicitation Number: BAA-20-100-SOL-0002
Notice Type: SOLICIT
NAICS: 541715
Notice Published: 11-24-21
Response Due: 02-03-23

Agency: Department of Health and Human Services
Office: OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Contact: Troy Francis - Contracting Officer (Team Lead), DRIVe This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Address: Washington, DC 20201
Place of Performance: Washington, DC 20201

Related Notices:
        08-23-21 SOLICIT

        08-23-21 SOLICIT

        11-10-21 SOLICIT


Click for official SAM (FBO) notice, additional information, and accompanying attachments

11/24/2021 - Please see Special Instructions 017 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 017, BARDA is hereby pausing "AOI #6: Beyond the Needle" until further notice. 11/10/2021 - Please see Special Instructions 016 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions 016, BARDA is re-opening "AOI #5: ReDirect (Repurposing Drugs in Response to Chemical Threats)" as part of its EZ-BAA (BAA-20-100-SOL-0002). 10/21/2021 -Please see Special Instructions 015Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 015, BARDA is announcing the following as part of its EZ-BAA: Add "AOI #12:Mitigating Long-term Effects (MILE) of Respiratory Distress" to the EZ-BAA. Notify potential Respondents that any EZ-BAA contracts (above the micro-purchase threshold) awarded on or after November 14, 2021 will be subject to Class Deviation (2021-03) from the Federal Acquisition Regulation (FAR) Regarding Implementation of Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors. Remind potential Respondents that the following AOIs under the EZ-BAA are currently open and accepting abstract submissions: AOI #2:Infection Severity and Solving Sepsis AOI #6: Beyond the Needle AOI #8: Bringing Laboratory Testing to the Home AOI #9: Digital Health Tools for Pandemic Preparedness AOI #10: Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens AOI #11a:Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 AOI #11b:Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection AOI #12:Mitigating Long-term Effects (MILE) of Respiratory Distress 8/23/2021 - Please see Special Instructions 014 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions 014, BARDA is announcing the following as part of its EZ-BAA: Close Area of Interest (AOI) #1 supporting the Early Notification to Act, Control, and Treat (ENACT) program. Pause AOI #7 supporting the ImmuneChip+ program until further notice. Remind : AOI #8:Bringing Laboratory Testing to the Home AOI #9: Digital Health Tools for Pandemic Preparedness AOI #10: Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens AOI #11a:Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 AOI #11b:Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection 3/4/2021 -Please see Special Instructions 013Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 013, BARDA is now accepting abstract submissions for "AOI #7: ImmuneChip+as part of its EZ-BAA (BAA-20-100-SOL-0002). 10/22/2020 - Please see Special Instructions 012 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 012, BARDA is now accepting abstract submissions for "AOI #1: ENACT (Early Notification to Act, Control and Treat) and "AOI#2: Infection Severity & Solving Sepsis.Additionally, AOI #4.3: Alternative Routes of Administration (AROA) for Vaccines is nowAOI #6: Beyond the Needle. 10/1/2020 - Please see Special Instructions 011Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions 011, BARDA is now accepting abstract submissions for"Area of Interest #5: ReDIRECT (Repurposing Drugs In Response to Chemical Threats)" as part of its EZ-BAA (BAA-20-100-SOL-0002). 7/9/2020 - Please seeSpecial Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions 010, BARDA is adding topic #4.1-E under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 6/29/2020 - Please see Special Instructions 009Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions 009, BARDA is revising topics #4.1-D and #4.3 immediately, and extending the closing date to 2359 HRS ET on 31 October 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 6/4/2020 - Amendment 001 to the EZ-BAA is now included as an attachment. Amendment 001 revises Section C of the EZ-BAA. Please also see Special Instructions 008Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 008, BARDA is revising topic#4.3 immediately,and closing topic#4.4 at 1700 HRS ET on 05 June 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 5/12/2020 - Please see Special Instructions 007Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 007, BARDA is closing topics #4.1-B and #4.1-Cunder its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 4/27/2020 -Please see Special Instructions 006Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 006, BARDA is adding topic #4.1-Dunder its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 4/2/2020 -Please see Special Instructions 005Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 005, BARDA is closing topic #4.1-A and revising topic #4.1-Cunder its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 3/18/2020 -Please see Special Instructions 004Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 004, BARDA is closing topic #4.2 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 3/9/2020 -Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002). 2/15/2020 - Please see Special Instructions 002 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDAis adding a new topic under its temporary AOI #4: 2019-nCoV as part of its EZ-BAA (BAA-20-100-SOL-0002). 2/3/2020 - Please see Special Instructions 001 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of its EZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. 2/3/2020 - See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR). Abstract submissions selected for award are considered to be the result of full and open competition and in full compliance with 41 U.S.C. 3301.